✦ LIBER ✦

PCN25 COST-EFFECTIVENESS ANALYSIS OF ERLOTINIB VERSUS DOCETAXEL AS A SECOND- OR THIRD-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN KOREA

✍ Scribed by Kim, YG; Lee, EK

Book ID: 122228454
Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 65 KB
Volume: 13
Category: Article
ISSN: 1098-3015
DOI: 10.1016/S1098-3015(11)73117-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN90 Cost-Effectiveness Analysis of Erl

PCN90 Cost-Effectiveness Analysis of Erlotinib Versus Docetaxel, Pemetrexed for Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer in Russia

✍ Nguyen, T.T.T.; Yagudina, R.; Kulikov, A. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

PCN37 Cost Comparison of Erlotinib Versu

PCN37 Cost Comparison of Erlotinib Versus Generic Docetaxel in Second-Line Non-Small Cell Lung Cancer in Italy

✍ Schwander, B.; Ravera, S.; Giuliani, G.; Nuijten, M.; Walzer, S. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

Randomized Phase III Trial of Erlotinib

Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)

✍ Kawaguchi, T.; Ando, M.; Asami, K.; Okano, Y.; Fukuda, M.; Nakagawa, H.; Ibata, 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 183 KB

An economic analysis of erlotinib, docet

An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer

✍ A. Araújo; B. Parente; R. Sotto-Mayor; E. Teixeira; T. Almodôvar; F. Barata; H. 📂 Article 📅 2008 🏛 Elsevier ⚖ 288 KB

PCN6: MODELLING THE COST-EFFECTIVENESS O

PCN6: MODELLING THE COST-EFFECTIVENESS OF DOCETAXEL IN THE SECOND LINE TREATMENT OF NON-SMALL-CELL LUNG CANCER (NSCLC)

✍ P Sharplin; UK Bose; J Holmes 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 52 KB

PCN82 Cost-Effectiveness Analysis of Erl

PCN82 Cost-Effectiveness Analysis of Erlotinib Versus Platinum Based Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer EGFR Activating Mutations

✍ P. Garrido; G. López-Vivanco; R. Rosell; B. Espinós; A. Castro-Gomez 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB